These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1878587)

  • 1. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation.
    Bianco JA; Appelbaum FR; Nemunaitis J; Almgren J; Andrews F; Kettner P; Shields A; Singer JW
    Blood; 1991 Sep; 78(5):1205-11. PubMed ID: 1878587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline: a prospective, randomized trial.
    Attal M; Huguet F; Rubie H; Charlet JP; Schlaifer D; Huynh A; Laurent G; Pris J
    Blood; 1993 Aug; 82(3):732-6. PubMed ID: 8338943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous pentoxifylline failed to prevent transplant-related toxicities in allogeneic bone marrow transplant recipients.
    Stockschläder M; Kalhs P; Peters S; Zeller W; Krüger W; Kabisch H; Lechner K; Zander A
    Bone Marrow Transplant; 1993 Oct; 12(4):357-62. PubMed ID: 8275035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pentoxifylline, ciprofloxacin and prednisone failed to prevent transplant-related toxicities in bone marrow transplant recipients and were associated with an increased incidence of infectious complications.
    Ferrà C; de Sanjosé S; Lastra CF; Martí F; Mariño EL; Sureda A; Brunet S; Gallardo D; Berlanga JJ; García J; Grañena A
    Bone Marrow Transplant; 1997 Dec; 20(12):1075-80. PubMed ID: 9466281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pentoxifylline is not useful in the prevention of toxicity associated with bone marrow transplantation].
    López J; Cancelas JA; Valiño JM; García-Laraña J; Sastre JL; Pérez-Oteyza J; Cerveró C; García-Avello A; Cabezudo E; Arranz MI
    Med Clin (Barc); 1994 Apr; 102(13):485-8. PubMed ID: 8208006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pentoxifylline on regimen related toxicity in patients undergoing allogeneic or autologous bone marrow transplantation.
    van der Jagt RH; Pari G; McDiarmid SA; Boisvert DM; Huebsch LB
    Bone Marrow Transplant; 1994 Feb; 13(2):203-7. PubMed ID: 8205090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constant intravenous pentoxifylline infusions in allogeneic marrow transplant recipients: results of a dose escalation study.
    Beelen DW; Sayer HG; Franke M; Scheulen ME; Quabeck K; Mohnke M; Oidtmann M; Schaefer UW
    Bone Marrow Transplant; 1993 Oct; 12(4):363-70. PubMed ID: 8275036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation.
    Clift RA; Bianco JA; Appelbaum FR; Buckner CD; Singer JW; Bakke L; Bensinger WI; Bowden RA; McDonald GB; Schubert M
    Blood; 1993 Oct; 82(7):2025-30. PubMed ID: 8400255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation.
    Van Lint MT; Uderzo C; Locasciulli A; Majolino I; Scimé R; Locatelli F; Giorgiani G; Arcese W; Iori AP; Falda M; Bosi A; Miniero R; Alessandrino P; Dini G; Rotoli B; Bacigalupo A
    Blood; 1998 Oct; 92(7):2288-93. PubMed ID: 9746766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha gene polymorphisms are associated with severity of acute graft-versus-host disease following matched unrelated donor bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium study.
    Goyal RK; Lin Y; Schultz KR; Ferrell RE; Kim Y; Fairfull L; Livote E; Yanik G; Atlas M
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):927-936.e1. PubMed ID: 20100586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation.
    Nemunaitis J; Buckner CD; Appelbaum FR; Higano CS; Mori M; Bianco J; Epstein C; Lipani J; Hansen J; Storb R
    Blood; 1991 May; 77(9):2065-71. PubMed ID: 1902125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group.
    List AF; Maziarz R; Stiff P; Jansen J; Liesveld J; Andrews F; Schuster M; Wolff S; Litzow M; Karanes C; Dahlberg S; Kirkhart B; Bianco JA; Singer JW
    Bone Marrow Transplant; 2000 Feb; 25(3):283-91. PubMed ID: 10673700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation.
    Nemunaitis J; Rosenfeld CS; Ash R; Freedman MH; Deeg HJ; Appelbaum F; Singer JW; Flomenberg N; Dalton W; Elfenbein GJ
    Bone Marrow Transplant; 1995 Jun; 15(6):949-54. PubMed ID: 7581096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
    Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
    Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation.
    Schmitz N; Bacigalupo A; Hasenclever D; Nagler A; Gluckman E; Clark P; Bourquelot P; Greinix H; Frickhofen N; Ringdén O; Zander A; Apperley JF; Gorin C; Borkett K; Schwab G; Goebel M; Russell NH; Gratwohl A
    Bone Marrow Transplant; 1998 May; 21(10):995-1003. PubMed ID: 9632272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation.
    De Witte T; Gratwohl A; Van Der Lely N; Bacigalupo A; Stern AC; Speck B; Schattenberg A; Nissen C; Gluckman E; Fibbe WE
    Blood; 1992 Mar; 79(5):1359-65. PubMed ID: 1536959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.